OrbiMed Reveals 7.2% Stake in Scribe Therapeutics, Assembled via IPO and Preferred Conversion

summarizeSummary

OrbiMed Advisors disclosed a 7.2% stake in Scribe Therapeutics, built through a $15 million IPO purchase and conversion of $31 million in preferred stock. The filing confirms a major institutional backer with board representation.

check_boxKey Events · Ownership and Investor Activity · SCTX

• OrbiMed Builds 7.2% Stake

  OrbiMed Advisors and OrbiMed Capital GP VIII acquired 1,348,825 shares, representing 7.2% of Scribe's outstanding common stock, through a combination of Series B preferred stock conversion and IPO purchases.

• Stake Valued at ~$25M at IPO Price

  The position was built via 2,065,672 Series B preferred shares (converted at 1-for-0.1689 into 348,825 common shares) and 1,000,000 shares bought in the IPO at $15.00 each, for a total cost basis of approximately $46 million.

• Board Representation

  Carl L. Gordon, a member of OrbiMed Advisors, serves on Scribe's board of directors, giving the investment group direct influence over corporate strategy.

• 180-Day Lock-Up Restricts Immediate Sales

  All shares are subject to a 180-day lock-up agreement expiring in late January 2027, preventing any near-term selling pressure from this stake.

auto_awesomeAnalysis · SCTX · Life Sciences

Just days after Scribe Therapeutics went public, OrbiMed Advisors—a leading healthcare investment firm—has accumulated a 7.2% stake. The position combines a $15 million IPO purchase at $15.00 per share with the conversion of $31 million in Series B preferred stock. Because OrbiMed partner Carl Gordon sits on Scribe's board, this represents a powerful institutional endorsement from a specialist investor. However, the 180-day lock-up means the overhang won't hit the market until late January 2027.